128 related articles for article (PubMed ID: 33187685)
21. Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience.
Hammas N; Laila C; Youssef AL; Hind el F; Harmouch T; Siham T; Afaf A
Diagn Pathol; 2012 Sep; 7():130. PubMed ID: 23016917
[TBL] [Abstract][Full Text] [Related]
22. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma.
Cai Y; Mohseny AB; Karperien M; Hogendoorn PC; Zhou G; Cleton-Jansen AM
J Pathol; 2010 Jan; 220(1):24-33. PubMed ID: 19882675
[TBL] [Abstract][Full Text] [Related]
23. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
24. Sclerostin expression in skeletal sarcomas.
Shen J; Meyers CA; Shrestha S; Singh A; LaChaud G; Nguyen V; Asatrian G; Federman N; Bernthal N; Eilber FC; Dry SM; Ting K; Soo C; James AW
Hum Pathol; 2016 Dec; 58():24-34. PubMed ID: 27498059
[TBL] [Abstract][Full Text] [Related]
25. Osteocalcin and osteonectin immunoreactivity in extraskeletal osteosarcoma: a study of 28 cases.
Fanburg-Smith JC; Bratthauer GL; Miettinen M
Hum Pathol; 1999 Jan; 30(1):32-8. PubMed ID: 9923924
[TBL] [Abstract][Full Text] [Related]
26. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma.
Ordóñez NG
Adv Anat Pathol; 2014 Jan; 21(1):63-7. PubMed ID: 24316906
[TBL] [Abstract][Full Text] [Related]
27. H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases.
Leinauer B; Wolf E; Werner M; Baumhoer D; Breining T; Luebke AM; Maas R; Schultheiß M; von Baer A; Sufi-Siavach A; Moritz C; Geißler S; Mellert K; Möller P; Barth TFE; Jundt G
Histopathology; 2021 Nov; 79(5):720-730. PubMed ID: 33991114
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.
Strickland S; Parra-Herran C
Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone.
Lee CH; Espinosa I; Jensen KC; Subramanian S; Zhu SX; Varma S; Montgomery KD; Nielsen TO; van de Rijn M; West RB
Mod Pathol; 2008 May; 21(5):531-9. PubMed ID: 18192965
[TBL] [Abstract][Full Text] [Related]
30. Chondroblastoma of bone. A clinical, radiological, light and immunohistochemical study.
Edel G; Ueda Y; Nakanishi J; Brinker KH; Roessner A; Blasius S; Vestring T; Müller-Miny H; Erlemann R; Wuisman P
Virchows Arch A Pathol Anat Histopathol; 1992; 421(4):355-66. PubMed ID: 1384228
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas.
Yoshikawa H; Rettig WJ; Lane JM; Takaoka K; Alderman E; Rup B; Rosen V; Healey JH; Huvos AG; Garin-Chesa P
Cancer; 1994 Aug; 74(3):842-7. PubMed ID: 8039112
[TBL] [Abstract][Full Text] [Related]
32. [Cell proliferation in bone tumors. Immunohistologic study of Ki-67 protein expression].
Stenzel I; Pösl M; Ritzel H; Hentz M; Werner M; Delling G
Pathologe; 1996 Jan; 17(1):56-62. PubMed ID: 8685097
[TBL] [Abstract][Full Text] [Related]
33. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
34. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
[TBL] [Abstract][Full Text] [Related]
35. Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma.
Lam SW; Cleven AHG; Kroon HM; Briaire-de Bruijn IH; Szuhai K; Bovée JVMG
Virchows Arch; 2020 Mar; 476(3):455-463. PubMed ID: 31768625
[TBL] [Abstract][Full Text] [Related]
36. Osteoid osteoma: the uniquely innervated bone tumor.
O'Connell JX; Nanthakumar SS; Nielsen GP; Rosenberg AE
Mod Pathol; 1998 Feb; 11(2):175-80. PubMed ID: 9504688
[TBL] [Abstract][Full Text] [Related]
37. Sclerosing epithelioid fibrosarcoma of bone: morphological, immunophenotypical, and molecular findings of 9 cases.
Kosemehmetoglu K; Ardic F; Kilpatrick SE; Aydingoz U; Sumathi VP; Michal M
Virchows Arch; 2021 Apr; 478(4):767-777. PubMed ID: 33084978
[TBL] [Abstract][Full Text] [Related]
38. Dentine matrix protein 1 (DMP-1) is a marker of bone-forming tumours.
Kashima TG; Dongre A; Oppermann U; Athanasou NA
Virchows Arch; 2013 May; 462(5):583-91. PubMed ID: 23559304
[TBL] [Abstract][Full Text] [Related]
39. SOX9 and SATB2 immunohistochemistry cannot reliably distinguish between osteosarcoma and chondrosarcoma on biopsy material.
Sharma AE; Pytel P; Cipriani NA
Hum Pathol; 2022 Mar; 121():56-64. PubMed ID: 35016891
[TBL] [Abstract][Full Text] [Related]
40. SATB2 is not a reliable diagnostic marker for distinguishing between oral osteosarcoma and fibro-osseous lesions of the jaws.
Grad-Akrish S; Rachmiel A; Ben-Izhak O
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 May; 131(5):572-581. PubMed ID: 33309262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
